|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Malignant Mesothelioma | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Mesothelioma | |||||
| 3 | More general conditions related to this trial | ||||
| Adenoma | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Neoplasms, Mesothelial | |||||
| 4 | Interventions listed in this trial | ||||
| carboplatin | |||||
| gemcitabine hydrochloride | |||||
| pemetrexed disodium | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Gemcitabine | |||||
| Pemetrexed | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anti-Infective Agents | |||||
| Antimetabolites | |||||
| Antimetabolites, Antineoplastic | |||||
| Antineoplastic Agents | |||||
| Antiviral Agents | |||||
| Enzyme Inhibitors | |||||
| Folic Acid Antagonists | |||||
| Immunologic Factors | |||||
| Immunosuppressive Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Radiation-Sensitizing Agents | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Eastern Cooperative Oncology Group | |||||
| National Cancer Institute (NCI) | |||||
| North Central Cancer Treatment Group | |||||